Biomarkers /
TNFRSF17
Overview
Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17) is a gene that encodes a protein that functions in B cell development and autoimmune response. The protein also functions in NF-kappaB and MAPK8/JNK activation. Missense mutations, silent mutations, frameshift insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
TNFRSF17 is altered in 0.50% of all cancers with colorectal adenocarcinoma, colon adenocarcinoma, glioblastoma, lung adenocarcinoma, and melanoma having the greatest prevalence of alterations [3].
The most common alterations in TNFRSF17 are TNFRSF17 A54T (0.08%), TNFRSF17 C21S (0.08%), TNFRSF17 E151K (0.08%), TNFRSF17 N91S (0.08%), and TNFRSF17 P145S (0.08%) [3].
Clinical Trials
Significance of TNFRSF17 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.